Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HLS TherapeuticsTSX:HLS -1.20%67 Debt-to-EBITDA is 2.72 as of Mar. 2026, which is 41% below its 10-year median of 4.62. GuruFocus rates TSX:HLS with a GF Score™ of 67/100 and a GF Value™ of C$4.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, HLS Therapeutics ranks worse than 63.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for HLS Therapeutics's Debt-to-EBITDA or its related term are showing as below:
TSX:HLS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.51 Med: 4.62 Max: 6.8
Current: 2.55
During the past 13 years, the highest Debt-to-EBITDA Ratio of HLS Therapeutics was 6.80. The lowest was 2.51. And the median was 4.62.
TSX:HLS's Debt-to-EBITDA is ranked worse than 63.48% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs TSX:HLS: 2.55
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
HLS Therapeutics Debt-to-EBITDA Related Terms
HLS Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
HLS Therapeutics (TSX:HLS) has a Debt-to-EBITDA of 2.72 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HLS Therapeutics. This is 41% below median its historical median of 4.62. Over the past decade, HLS Therapeutics' Debt-to-EBITDA has ranged from 2.51 to 6.80. According to the industry distribution chart, HLS Therapeutics ranks #438 out of 690 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is HLS Therapeutics' Debt-to-EBITDA too high?
HLS Therapeutics' current Debt-to-EBITDA of 2.72 is 41% below median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 2.51 to a high of 6.80. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. HLS Therapeutics' value of 2.72 is 61.9% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #438 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #438 out of 690 companies for Debt-to-EBITDA. This places HLS Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. HLS Therapeutics' value of 2.72 is 61.9% above this benchmark. Historically, HLS Therapeutics' own Debt-to-EBITDA has ranged from 2.51 to 6.80 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 1.68, HLS Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current Debt-to-EBITDA of 2.72 is 61.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HLS Therapeutics. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current Debt-to-EBITDA is 2.72, which is 41% below median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.49, compared to a current price of C$4.11 — trading 8.5% below its estimated fair value. The current Debt-to-EBITDA is 2.72, which is 41% below median its 10-year median of 4.62 and 61.9% above the Drug Manufacturers industry median of 1.68. HLS Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Debt-to-EBITDA is 2.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.11 is trading 8.5% below its estimated GF Value™ of C$4.49.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Debt-to-EBITDA: 2.72 (41% below median its 10-year median of 4.62)
GF Value™: C$4.49 vs. price of C$4.11 (8.5% below fair value)
Industry Position: 61.9% above the Drug Manufacturers median (#438 of 690)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score
Get the complete analysis for TSX:HLS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
